Breast cancer drug CANMAb will start being sold next month, February 2014, in India. CANMAb was developed by the biotechnology company Biocon and the US-based Mylan. Interestingly, the price for the Indian market is significantly lower than other more developed markets.
Here is the news story from The Economic Times:
"The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.
The Economic Times: http://articles.economictimes.indiatimes.com/2014-01-18/news/46324991_1_breast-cancer-drug-herceptin-canmab